TQB2102

TQB2102 is an antibody-drug conjugate developed by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical and Chia Tai Tianqing Pharmaceutical. Its target is HER2 (the sponsor names HER2). The sponsor states: Described on the study page as a next-generation HER2 antibody-drug conjugate carrying the small-molecule toxin TQ22723. ClinicalTrials.gov describes the intervention as: TQB2102 is a next-generation HER2 Antibody-Drug Conjugate drug proposed for patients with HER2 positive Recurrent/Metastatic Breast Cancer. It is the investigational product in 8 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07003074 (A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer), NCT06561607 (A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer) and NCT07008976 (Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer), in HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, biliary tract cancer and non-small-cell lung cancer. The largest, NCT07003074, plans to enrol 642 participants with primary completion expected 2029-07. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.